FDA Recommends Recall of Artificial Eye Ointment for Potential Bacterial Contamination
This warning is the second on top of a previous warning not to purchase or use EzriCare Artificial Tears or Delsam Pharma’s Artificial Tears due to potential bacterial contamination.
FDA is warning consumers and health care professionals of the use of Delsam Pharma’s Artificial Eye Ointment because of potential bacterial contamination. This warning is the second on top of a previous warning not to purchase or use EzriCare Artificial Tears or Delsam Pharma’s Artificial Tears due to potential bacterial contamination.
These over-the-counter products are manufactured by Global Pharma Healthcare Private Limited and are intended to be sterile. The use of the ointment can increase the risk of eye infections that can result in blindness according to FDA, and patients who have signs or symptoms of an eye infection should talk to their health care provider or seek medical care immediately warns the agency. FDA recommended that Global Pharma recall Delsam Pharma’s Artificial Eye Ointment on February 22, 2023.
Source: FDA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
